Multiple Sclerosis and Related Disorders

Papers
(The TQCC of Multiple Sclerosis and Related Disorders is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Test-retest reliability of the Swedish version of the Modified Fatigue Impact Scale in people with mild to moderate multiple sclerosis72
Psychometric measurement properties and reference values of the six-spot step test, the six-minute walk test, the 25-foot walk test, and the 12-item multiple sclerosis walking scale in people with mul58
Preliminary race-ethnicity-based analyses of fall risk among people with multiple sclerosis58
Characteristics of Patients with Newly Diagnosed Multiple Sclerosis: A Five-Year Study at Benghazi Medical Center, Benghazi, Libya57
Real-World Evidence with Five-Year Data (2017-2022) on the Use of Cladribine Tablets in Patients with Multiple Sclerosis in England: an Updated Analysis from the CLARENCE Study47
EDSS and Infratentorial White Matter Lesion Volume are Considered Predictors of Fatigue Severity in RRMS46
The Management of Lower Urinary Tract Symptoms in Multiple Sclerosis: an Umbrella Review45
Reconciling lesions, relapses and smouldering associated worsening: A unifying model for multiple sclerosis pathogenesis45
Influence of Cigarette, and Waterpipe Smoking, Alcohol, and Drug Consumption on the Occurrence of Late-Onset Multiple Sclerosis45
Functional electrical stimulation combined with voluntary cycling accentuates VO2 response in people with severe multiple sclerosis: A pilot study44
57. Cognitive Decline and Motor Handicap in Multiple Sclerosis Patients40
Cognitive outcomes in late-onset versus adult-onset Multiple Sclerosis40
Coexistence of epilepsy or seizure and multiple sclerosis; a single center experience39
143. Navigating the Maze of Multiple Sclerosis Disease Modifying Therapies: Insights from Iran's National MS Registry39
Multiple sclerosis disease-modifying therapy use in the department of veteran affairs and Medicare: A comparative analysis38
Impact of insurance status on MRI phenotypes in MS38
157. Remibrutinib Exposure in Cerebrospinal Fluid: Insights from a Study in Healthy Subjects37
125. Investigating Psychoses in Pediatric-Onset Multiple Sclerosis: A Systematic Review of Case Reports36
Markedly elevated cerebrospinal fluid white blood cell count in multiple sclerosis: How high is too high?35
Lipid measures are associated with cognitive functioning in multiple sclerosis patients35
Symptoms of PTSD and depression in newly diagnosed people with multiple sclerosis during the outbreak Oct.7th war on Gaza: A case-control study from Jordan35
Macular vascular density alteration patterns in paediatric optic neuritis patients with serum MOG antibody positivity detected by optic coherence tomography angiography35
Can neurofilament lightchain as endpoint in Phase 2 derisk clinical disability worsening in Phase 3 in multiple sclerosis?34
Feasibility and usability evaluation of a gamified fatigue management mobile application for persons with multiple sclerosis in everyday life34
Self-reported cognitive function mediates the relationship between employment status and cognitive functioning in persons with multiple sclerosis34
Glucagon-like peptide-1 agonist safety and efficacy in a multiple sclerosis cohort34
Incidence of multiple sclerosis relapses and pseudo-relapses following COVID-19 vaccination34
Siponimod following Alemtuzumab in secondary progressive MS: investigating sequential therapy–A case series34
The relationship between cognitive impairment, cognitive fatigue, and visual evoked potential latency in people with multiple sclerosis33
Evaluation of the use of high-efficacy treatments (HETs) in patients with relapsing-remitting multiple sclerosis in Argentina33
Sarcopenia in patients with multiple sclerosis33
Markers of Epstein-Barr virus and Human Herpesvirus-6 infection and multiple sclerosis clinical progression32
Characterizing causal relationships of visceral fat and body shape on multiple sclerosis risk32
Comparison of SARS-CoV-2 antibody response after two doses of mRNA and inactivated vaccines in multiple sclerosis patients treated with disease-modifying therapies32
Sexual problems in MS: Sex differences and their impact on quality of life32
Evaluation of adherence to treatment in patients with multiple sclerosis from Latin America31
A one year follow of patients with multiple sclerosis during COVID-19 pandemic: A cross-sectional study in Qom province, Iran31
Plasma 24-hydroxycholesterol is associated with narrower common carotid artery and greater flow velocities in relapsing multiple sclerosis30
S1P receptor modulators in Multiple Sclerosis: Detecting a potential skin cancer safety signal30
Incidence of malignant neoplasms and mortality in people affected by multiple sclerosis in the epoch of disease-modifying treatments: A population-based study on Tuscan residents30
“It's on the tip of my tongue!” exploring confrontation naming difficulties in patients with multiple sclerosis30
Diagnosing ‘transition’ to secondary progressive multiple sclerosis (SPMS): A step-by-step approach for clinicians30
Leber Hereditary Optic Neuropathy Presenting as Bilateral Visual Loss and White Matter Disease29
Atherosclerosis and multiple sclerosis: An overview on the prevalence of risk factors28
Identification of common susceptibility genes and drug target genes in multiple sclerosis, systemic lupus erythematosus, and rheumatoid arthritis and its value to guide clinical treatment28
The effects of bupropion on sexual dysfunction in female patients with multiple sclerosis: A double-blind randomized clinical trial28
Involvement Peripheral Nerve System in Multiple Sclerosis27
Effects of constraint induced movement therapy in patients with multiple sclerosis: A systematic review27
The Use of Ocrelizumab in Pediatric Multiple Sclerosis Patients in the United Arab Emirates: A Retrospective Study27
Peripheral nerve vulnerability as risk factor for multiple sclerosis: Possible insights from Neurofibromatosis type 2 (NF2)27
Sexual Dysfunctions and Self-Esteem in Multiple Sclerosis: A Tunisian Study27
Reliability of mobile video-oculography in multiple sclerosis patients using an iPad: A prospective validation study26
Expert Opinion on COVID-19 Vaccination and the Use of Cladribine Tablets26
The Relationship Between Smoking and Multiple Sclerosis Severity in Saudi Arabia26
Risk factors for development of lymphopenia in dimethyl fumarate-treated patients with multiple sclerosis26
Relationship between cognitive disturbances and sleep disorders in multiple sclerosis is modulated by psychiatric symptoms25
Clinical and imaging features of patients with late-onset myelin oligodendrocyte glycoprotein antibody-associated disease25
Epidemiology of familial multiple sclerosis and its comparison to sporadic form in Markazi Province, Iran25
Characteristics of recurrence risk perception and coping strategies in patients with neuromyelitis optica spectrum disorder: A qualitative study24
Smoking, cardiovascular risk factors and LRP2 gene variation: Associations with disease severity, cognitive function and brain structure in primary progressive multiple sclerosis24
Dietary intake and characteristics in persons with multiple sclerosis24
Significant upregulation of prenyltransferase-related genes in neuromyelitis optica: Diagnostic potential and clinical correlations24
Prognostic factors of tumefactive demyelinating lesions and differential features for multiple sclerosis in etiology24
Discontinuation of first-line disease-modifying therapy in relapse onset multiple sclerosis24
How Much Is Enough? Determining Minimum Valid Tracking Periods for Reliable Physical Activity Monitoring24
Multiple Sclerosis in Elderly Patients: When We Can Stopped Treatment?24
Perspectives on fatigue management among veterans living with multiple sclerosis24
Index of cardiac-electrophysiological balance in relapsing–remitting multiple sclerosis patients treated with fingolimod24
Trait mindfulness, emotion dysregulation, and depression in individuals with multiple sclerosis24
Anti-Spike IgG in multiple sclerosis patients after BNT162b2 vaccine: An exploratory case-control study in Italy24
A systematic review and meta-analysis on gene-environment interaction effects on the associations of vitamin D and sun exposure with multiple sclerosis risk24
Traditional first-line treatment failure rates in neuromyelitis optica spectrum disorder patients included in the Argentinean registry (RelevarEM)24
Discontinuation of dimethyl fumarate in multiple sclerosis - a nationwide study23
Cladribine effects on emotional awareness and reasoning: The CLEAR study23
Switching from natalizumab to an anti-CD20 monoclonal antibody in relapsing remitting multiple sclerosis: A systematic review23
Clinical risk stratification: Development and validation of the DAAE score, a tool for estimating patient risk of transition to secondary progressive multiple sclerosis23
Predictors of Progression of Multiple Sclerosis in a Sample of Egyptian Patients23
Dynamic disability measures decrease the clinico-radiological gap in people with severely affected multiple sclerosis22
Carotid intima media thickness and multiple sclerosis22
Real World Study of Ocrelizumab in Multiple Sclerosis: Kuwait Experience22
Dysphagia in Relation with Depression, Anxiety, Fatigue, Sleep Quality, and Pain in Multiple Sclerosis22
The role of pregnancy in relapsing-remitting MS prognosis: A five-year study22
Prevalence and Clinical Characteristics of Urological Symptoms in Iranian Multiple Sclerosis Patients: Implications for Quality of Life and Management22
Management of patients with active relapsing-remitting or secondary progressive multiple sclerosis: A French real-world study based on claims data linked to a phase IV study22
Effects of submotor-threshold tibial nerve stimulation on plantarflexion torque in healthy adults and people with multiple sclerosis22
23. Vanishing Clues: A Systematic Review of Oligoclonal Band Disappearance in Multiple Sclerosis Patients after Treatment21
Central American and Caribbean consensus for the treatment of MS, NMOSD, and MOGAD21
Effects of inspiratory muscle training on balance, trunk control, fear of falling, respiratory function, and quality of life in people with multiple sclerosis: a randomized controlled trial21
Efficacy and safety of ocrelizumab in patients with relapsing multiple sclerosis: Real-world experience of two Swiss multiple sclerosis centers21
134. Impact of Bowel Dysfunction, Urinary Dysfunction, and Fatigue on Quality of Life in Multiple Sclerosis21
Cerebrospinal fluid indices as predictors of treatment response in autoimmune encephalitis21
Glial-mediated pathogenesis and intervention strategies in neuromyelitis optica spectrum disorder21
Efficacy and safety of ocrelizumab in pediatric multiple sclerosis21
Telehealth in Multiple Sclerosis: Fostering Quality of Life21
Early use of high efficacy therapies in pediatric forms of relapsing-remitting multiple sclerosis: A real-life observational study21
70. Real-World Experience of Cladribine Tablets in the Treatment of Multiple Sclerosis: An Omani Cohort from Khoula Hospital20
120. The Pathological Findings of the First Cervical Spine MRI of The Neuromyelitis Optica Spectrum Disorders Patients20
81. Gender Difference In Egyptian Patients With Multiple Sclerosis20
101. Pseudotumor Demyelinating Lesions in Inflammatory Diseases of the Central Nervous System: An Algerian Series20
95. Patterns of Corpus Callosum Lesions in Demyelinating Diseases of the Central Nervous System20
Exclusion of alternative diagnoses: A component of the 2023 MOGAD criteria that belongs at the forefront, not in the background20
67. Domain-Specific and Global Cognitive Impairment in Multiple Sclerosis Patients Based on Cambridge Neuropsychological Test Automated Battery20
41. Neuropathic Pain in Multiple Sclerosis20
30. Thalamic Volume Differentiates Multiple Sclerosis from Neuromyelitis Optica Spectrum Disorder20
165. Unmet Needs and Treatment of Relapsing-Remitting Multiple Sclerosis in Saudi Arabia: Focus on the Role of Ofatumumab20
Evaluation of functional outcome measures after fampridine treatment in patients with multiple sclerosis - An interventional follow-up study19
Response: Treatment of multiple sclerosis as a single disease based on the body-pathology-environment model19
Validation of the Self-Assessed Dynamic Gait Index in People with Multiple Sclerosis19
Neurological efficacy and safety of mesenchymal stem cells (MSCs) therapy in people with multiple sclerosis (pwMS): An updated systematic review and meta-analysis19
Effects of photobiomodulation therapy on muscle function in individuals with multiple sclerosis19
Reduced quality of life in a pediatric-onset Neuromyelitis optica spectrum disorders cohort19
Implementing Shared Decision-Making for Multiple Sclerosis: The MS-SUPPORT Tool19
Asymptomatic MRI lesions in pediatric-onset AQP4-IgG positive NMOSD19
Depression, Anxiety and Alexithymia in Tunisian Patients with Multiple Sclerosis19
Capacity of fullerenols to modulate neurodegeneration induced by ferroptosis: Focus on multiple sclerosis19
Pregnancy and Infant Outcomes in Women Receiving Ocrelizumab for the Treatment of Multiple Sclerosis: Analysis of the Largest Available Outcomes Database19
Clinical and MRI predictors of cognitive decline in patients with relapsing-remitting multiple sclerosis: A 2-year longitudinal study19
Cervical lymph node diameter reflects disease progression in multiple sclerosis19
Bio-Psycho-Social Model of Multiple Sclerosis (BPSMMS)19
Impact of multiple sclerosis on male sexual and reproductive health19
RETRACTED: New relapse of multiple sclerosis and neuromyelitis optica as a potential adverse event of AstraZeneca AZD1222 vaccination for COVID-1919
Quantifying the economic burden to patients of relapse events from neuromyelitis optica spectrum disorders: A cross-sectional survey18
Barriers to Engage in Physical Activity in People with Multiple Sclerosis in Jordan18
Adherence to Treatment in Multiple Sclerosis18
Efficacy of Virtual Reality Interventions on Mood and Cognition in Patients with Multiple Sclerosis. a Systematic Review18
Cytokines/chemokines and soluble immune checkpoint molecules in anti-GABAB receptor encephalitis18
Using MS induced pluripotent stem cells to investigate MS aetiology18
Is BDNF related to spatial-temporal gait parameters in people with multiple sclerosis? An observational study18
The Effect of Rituximab on Mood Disorders in Multiple Sclerosis18
Higher frequency of Human herpesvirus-6 (HHV-6) viral DNA simultaneously with low frequency of Epstein-Barr virus (EBV) viral DNA in a cohort of multiple sclerosis patients from Rio de Janeiro, Brazil18
Factors contributing to falls in people with multiple sclerosis: The exploration of the moderation and mediation effects18
Real-World Use of Cladribine Tablets (Completion Rates and Treatment Persistence) in Patients with Multiple Sclerosis in England: the CLARENCE Study18
Monkeypox in Multiple Sclerosis patients: Should we be alert?18
Effect of immersive virtual reality training on hand-to-mouth task performance in people with Multiple Sclerosis: A quantitative kinematic study18
Influence of physicians’ risk perception on switching treatments between high- efficacy and non–high-efficacy disease‑modifying therapies in multiple sclerosis18
Effect of high frequency repetitive transcranial magnetic stimulation (rTMS) on the balance and the white matter integrity in patients with relapsing-remitting multiple sclerosis: A long-term follow-u18
Cross-Cultural Adaptation and Psychometric Evaluation of the Physical Activity and Disability Survey - Revised in People with Multiple Sclerosis18
Social network size and mental health outcomes in youth with neuroinflammatory disorders17
Altered gene expression of miR-155 in peripheral blood mononuclear cells of Multiple sclerosis patients: Correlation with TH17 frequency, inflammatory cytokine profile and autoimmunity17
Racial and ethnic disparities in treatment response and tolerability in multiple sclerosis: A comparative study17
Smartphone monitoring of cognition in people with multiple sclerosis: A systematic review17
Levamisole-associated multifocal inflammatory encephalopathy: clinical and MRI characteristics, and diagnostic algorithm17
Natalizumab treatment of multiple sclerosis — a Danish nationwide study with 13 years of follow-up17
Practical issues concerning the use of Magnetic Resonance Imaging in Multiple Sclerosis in Latin America: Discussion from 16 centres on behalf of the Foro Latam EM Study Group17
Seroconversion after COVID-19 vaccination for multiple sclerosis patients on high efficacy disease modifying medications17
Weak grip strength among persons with multiple sclerosis having minimal disability is not related to agility or integrity of the corticospinal tract17
Significant retinal microvascular impairments in multiple sclerosis assessed through optical coherence tomography angiography17
Association of health behaviour and clinical manifestation in early multiple sclerosis in Germany – Baseline characteristics of the POWER@MS1 randomised controlled trial17
Peripheral neuropathy and MOG-IgG: A clinical and neuropathological retrospective study17
The prevalence and clinical phenotype of dual seropositive neuromyelitis optica spectrum disorders at a national reference center in South Asia17
Seasonal variation in attacks of neuromyelitis optica spectrum disorders and multiple sclerosis: Evaluation of 794 attacks from a nationwide registry in Argentina17
Upper cervical cord atrophy is independent of cervical cord lesion volume in early multiple sclerosis: A two-year longitudinal study17
153. Efficacy and Safety of Tolebrutinib Versus Placebo in Non-Relapsing Secondary Progressive Multiple Sclerosis: Results From the Phase 3 HERCULES Trial17
Evaluating the impact of systematic reporting of patient-reported outcome measures on depression and anxiety levels in people with multiple sclerosis: a randomized controlled trial17
Aerobic exercise increases irisin serum levels and improves depression and fatigue in patients with relapsing remitting multiple sclerosis: A randomized controlled trial17
Patients experiences when receiving diagnosis of multiple sclerosis: A qualitative systematic review17
Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting mul17
Microstructural alterations in different types of lesions and their perilesional white matter in relapsing-remitting multiple sclerosis based on diffusion kurtosis imaging17
Tixagevimab and Cilgavimab (Evusheld) Boosts Antibody Levels to SARS-Cov-2 in Patients with Multiple Sclerosis on B-Cell Depleters17
No difference in radiologic outcomes for natalizumab patients treated with extended interval dosing compared with standard interval dosing: Real-world evidence from MS PATHS17
106. Assessment of Depression and Anxiety in Patients with Multiple Sclerosis in Morocco16
MS in the UAE: Population Estimates of Anxiety, Depression and Health-Related Quality of Life16
Update on aquaporin-4 antibody detection: the early diagnosis of neuromyelitis optica spectrum disorders16
Feasibility and tolerability of portable, low-field brain MRI for patients with multiple sclerosis16
Seizures in inflammatory demyelinating disorders of the central nervous system16
Preferences for neuromyelitis optica spectrum disorder treatments: A conjoint analysis with neurologists in Spain16
124. The Prevalence of Iron Overload in Patients with Multiple Sclerosis in National Guard Health Affair Hospital, Riyadh Center from 2015-202116
Understanding use and predictors of compensatory cognitive strategies in people with multiple sclerosis16
Assessing disability progression using the WHODAS 2.0 in multiple sclerosis: Investigating clinical and socio-demographic factors in a large longitudinal cohort study (TONiC-MS)16
Association between clinical characteristics, acute steroid treatment and oligoclonal bands result in multiple sclerosis: A retrospective study16
Comparison of vision-related quality of life in NMOSD and MOGAD16
Effect of siponimod on retinal thickness, a marker of neurodegeneration, in participants with SPMS: Findings from the EXPAND OCT substudy16
Hospitalisations and humoral COVID-19 vaccine response in vaccinated rituximab-treated multiple sclerosis patients16
Multiple Sclerosis and biological definitions in neurodegenerative diseases16
Physical activity is associated with fatigue in persons newly diagnosed with multiple sclerosis16
Systematic review on the wearing-off phenomenon of disease-modifying therapies in managing multiple sclerosis16
Optical coherence tomography and visual evoked potential and its relationship with neurological disability in patients with relapsing-remitting multiple sclerosis16
Reduced physical activity in multiple sclerosis: The role of gait parameters, gait variability parameters and self-reported measure of gait16
Coenzyme Q10 supplementation in multiple sclerosis; A systematic review16
Connection between microstructural alterations detected by diffusion MRI and cognitive dysfunction in MS: A model-free analysis approach16
79. Sustained Treatment Persistence and High Adherence to Cladribine Tablets in Multiple Sclerosis: Results from Patient Support Program in Gulf Countries16
Clinical features of MOGAD with brainstem involvement in the initial attack versus NMOSD and MS15
Serum Oxidative Stress Biomarkers in Relapsing Remitting Multiple Sclerosis Patients with No Evidence of Disease Activity15
Validity and reliability of the Six-Minute Pegboard Ring Test for assessing functional capacity and upper limb function in persons with multiple sclerosis15
Risk of COVID-19 infection and severe disease in MS patients on different disease-modifying therapies15
Effects of six-month home-based neuro-functional and resistance training interventions on cognitive and motor performance in multiple sclerosis patients with cognitive impairment: A randomized control15
Self-reported fatigue impact is associated with frequency of falls and injurious falls in people with multiple sclerosis15
Mesenchymal stem cells in clinical trials for multiple sclerosis: A systematic literature review and review of clinical trials15
Bone loss and fracture in people with multiple sclerosis: A systematic review and meta-analysis15
Serum Neurofilament Light Chain as a Biomarker of Disease Progression in a Sample of Egyptian Multiple Sclerosis Patients15
Serum ocrelizumab concentrations in patients with multiple sclerosis: A cross-sectional study from routine healthcare15
Serum neurofilament light chain as a biomarker in multiple sclerosis: A cross-sectional observation in real-world clinical practice15
The effect of cooling garments to improve physical function in people with multiple sclerosis: A systematic review and meta-analysis15
Persistently reduced humoral and sustained cellular immune response from first to third SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients15
The influence of disease-modifying therapy on hidden disability burden in people with newly diagnosed relapsing-remitting multiple sclerosis15
MRI-based radiomics for differention of aquaporin 4-immunoglobulin G–positive neuromyelitis optic spectrum disorder and anti myelin oligodendrocyte glycoprotein immunoglobulin G–associated disorder15
Deciphering the bidirectional impact of leukocyte telomere length on multiple sclerosis progression: A Mendelian randomization study15
Sleep, physical activity, and psychological outcomes in children and adolescents with pediatric onset multiple sclerosis15
Allied health professionals knowledge and clinical practice in telehealth exercise behavioural change for multiple sclerosis15
Serum neurofilament light chain levels suggest neuroprotection following bexarotene-induced remyelination in people with relapsing remitting multiple sclerosis15
Long term effects of continuous positive airway pressure treatment of obstructive sleep apnea-hypopnea syndrome in multiple sclerosis patients15
Effectiveness of acceptance and commitment therapy for improving quality of life and mood in individuals with multiple sclerosis: A systematic review and meta-analysis15
Prognosis of walking function in multiple sclerosis supported by gait pattern analysis15
Variability of objective gait measures across the expanded disability status scale in people living with multiple sclerosis: A cross-sectional retrospective analysis15
The prevalence of Myocardial Infarction among Multiple Sclerosis Patients: a Systematic Review and Meta-analysis15
Prevalence and incidence of multiple sclerosis in the Netherlands15
Clinical risk factors for recurrence of myelin oligodendrocyte glycoprotein antibody-associated disease15
Investigating treatment alternatives for fingolimod in patients with multiple sclerosis developed refractory fingolimod-related genital Human Papilloma Virus (HPV) infection15
Additive beneficial effects of aerobic training and royal jelly on hippocampal inflammation and function in experimental autoimmune encephalomyelitis rats14
Quality of life, Knowledge and Access to Treatment in Times of Economic crisis in Lebanon14
Increased healthcare utilization in the year before multiple sclerosis diagnosis14
SARS-CoV-2 infection in patients with neuroimmunological disorders in a tertiary referral centre from the north of Portugal14
Multiple Sclerosis in Middle East North Africa (MENA) Region: Challenges, Achievements and Opportunities.14
Unwrapping the “black box” of balance training in people with multiple sclerosis – A descriptive systematic review of intervention components, progression, and intensity14
Telemedicine and Multiple Sclerosis Management in the Era of COVID-19, Al-Azhar Experience14
Are we ready for CD19-targeted CAR T-cell therapies in MS?14
Effects of Cognitive and Motor Secondary Tasks on Gait Performance in Healthy Controls and Multiple Sclerosis Patients with and Without Fall History14
Hypogonadism in men with multiple sclerosis: Prevalence and clinical associations14
Transcranial direct current stimulation for spasticity in patients with multiple sclerosis: Exploring novel routes14
The effect of COVID-19 lockdowns on exercise and the role of online exercise in Australians with multiple sclerosis14
Effectiveness and safety of switching to teriflunomide in older patients with relapsing multiple sclerosis: A real-world retrospective multicenter analysis14
Prevalence of Urinary Tract Symptoms in Patients with Multiple Sclerosis and Health Care Seeking Behavior: A Cross Sectional Study in Riyadh, Saudi Arabia.14
Navigating the discontinuation of multiple sclerosis first line treatments: A paradigm shift in patient care14
Clinical characteristics, sero- prevalence, treatment and outcomes of AQP4 IgG associated neuromyelits optic spectrum disorder (NMOSD) in Sri Lanka14
Range of motion abnormalities in the lower limb joints during gait in youth with multiple sclerosis14
Emerging trends in multiple sclerosis research14
The serum kynurenine pathway metabolic profile is associated with overweight and obesity in multiple sclerosis14
Comparative efficacy and safety of ozanimod and ponesimod for relapsing multiple sclerosis: A matching-adjusted indirect comparison14
Clinical Characteristics of Switching Between Disease Modifying Drugs Among a Sample of Egyptian Multiple Sclerosis Patients14
High-efficacy therapy reduces subcortical grey matter volume loss in Japanese patients with relapse-onset multiple sclerosis: A 2-year cohort study14
Psychotherapy and professional psychological support in multiple sclerosis: Uncovering patients’ patterns of access and preferences14
Ocrelizumab during pregnancy and lactation: Rationale and design of the MINORE and SOPRANINO studies in women with MS and their infants14
Neural Substrates of Mobility and Postural Impairments in People with Multiple Sclerosis14
Aggressive Pediatric Multiple Sclerosis: Features and therapeutic Challenges14
Linking X to MS: Immunity and demyelination on the X-chromosome in MS14
Anti-HBs titers are not decreased after treatment with oral Cladribine in patients with Multiple Sclerosis vaccinated against Hepatitis B virus13
Short and mid-term research priorities for Veterans with multiple sclerosis: A modified Delphi process engaging Veterans, researchers, and operational partners13
Aims & Scope & Editorial Board13
Cognitive Impairment in Multiple Sclerosis: the Role of Sleep Disorders13
Can we improve outcomes in MS around the world? Access and global considerations across income strata13
31. Quantitative susceptibility mapping (QSM)-based regional iron concentration: Does it correlate with brain volume loss? An analysis of 250 regions of interest (ROIs)13
Parenchymal Neuro-Behçet's disease or Comorbid Behçet's disease with multiple sclerosis: A discriminative analysis of a complex clinical entity13
Longitudinal change of serum NfL as disease activity biomarker candidate in MOGAD: A descriptive cohort study13
Investigating the impact of different dichotomous definitions for cognitive impairment on functional connectivity in secondary progressive MS13
The Association of ApoE Genotype and Cognitive Impairment in Multiple Sclerosis (MS): A Systematic Review and Meta-Analysis13
Effect of alemtuzumab on fatigue, quality of life, and patient/caregiver-reported outcomes in relapsing-remitting multiple sclerosis—A real-world evidence study13
Rapid depletion of CD20+ B and T cells following ofatumumab therapy onset13
Cross-cultural adaptation, content validity, test-retest reproducibility and reliability of the reintegration to normal living index: Brazilian Portuguese version13
Revolutionizing MS Care and Research: Inside Iran's Nationwide Multiple Sclerosis Registry13
Optic Nerve Imaging Solving Demyelination Mystery13
0.16547298431396